Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BSEM BioStem Technologies	$13.11 -7.3%	$12.99	$6.95 ▼ $28.26	$218.99M	-0.32	49,416 shs	25,536 shs
COLL Collegium Pharmaceutical	$29.60 +0.5%	$28.50	$23.23 ▼ $42.29	$951.10M	0.63	412,042 shs	200,611 shs
MDXG MiMedx Group	$5.90 +0.9%	$6.65	$5.47 ▼ $10.14	$871.44M	1.82	686,098 shs	631,553 shs
PNTG The Pennant Group	$28.06 +0.7%	$27.60	$21.18 ▼ $37.13	$967.20M	1.51	226,895 shs	97,463 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BSEM BioStem Technologies	0.00%	-5.68%	+9.06%	+21.16%	+85.96%
COLL Collegium Pharmaceutical	0.00%	0.00%	-1.20%	-1.50%	-7.93%
MDXG MiMedx Group	0.00%	-3.59%	-17.71%	-25.69%	-14.62%
PNTG The Pennant Group	0.00%	+1.15%	-4.66%	+19.91%	+23.89%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BSEM BioStem Technologies	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
COLL Collegium Pharmaceutical	3.8398 of 5 stars	3.4	1.0	0.0	3.0	2.3	0.8	1.9
MDXG MiMedx Group	3.4729 of 5 stars	3.5	3.0	0.0	0.0	1.3	3.3	1.9
PNTG The Pennant Group	2.5396 of 5 stars	2.3	4.0	0.0	0.0	1.2	2.5	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BSEM BioStem Technologies	0.00	N/A	N/A	N/A
COLL Collegium Pharmaceutical	2.75	Moderate Buy	$43.75	47.80% Upside
MDXG MiMedx Group	3.00	Buy	$12.50	111.86% Upside
PNTG The Pennant Group	2.60	Moderate Buy	$34.60	23.31% Upside

Current Analyst Ratings Breakdown

Latest BSEM, COLL, PNTG, and MDXG Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/10/2025	PNTG The Pennant Group	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$35.00
6/3/2025	PNTG The Pennant Group	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$30.00 ➝ $31.00
5/12/2025	PNTG The Pennant Group	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$28.00 ➝ $32.00
5/9/2025	COLL Collegium Pharmaceutical	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$36.00 ➝ $37.00
4/9/2025	COLL Collegium Pharmaceutical	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$46.00 ➝ $46.00
4/2/2025	PNTG The Pennant Group	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$38.00 ➝ $38.00
3/24/2025	COLL Collegium Pharmaceutical	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00 ➝ $50.00

(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BSEM BioStem Technologies	$301.83M	0.73	N/A	N/A	N/A	∞
COLL Collegium Pharmaceutical	$631.45M	1.51	$12.33 per share	2.40	$7.10 per share	4.17
MDXG MiMedx Group	$348.88M	2.50	$0.33 per share	17.81	$1.31 per share	4.50
PNTG The Pennant Group	$695.24M	1.39	$0.92 per share	30.43	$9.08 per share	3.09

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BSEM BioStem Technologies	N/A	$1.47	8.92	5.72	N/A	N/A	N/A	N/A	8/11/2025 (Estimated)
COLL Collegium Pharmaceutical	$69.19M	$1.22	24.26	4.92	N/A	6.61%	99.08%	15.14%	8/6/2025 (Estimated)
MDXG MiMedx Group	$42.42M	$0.27	21.85	18.44	N/A	11.40%	22.70%	16.77%	7/30/2025 (Estimated)
PNTG The Pennant Group	$22.56M	$0.76	36.92	31.89	2.39	3.40%	10.73%	4.00%	8/5/2025 (Estimated)

Latest BSEM, COLL, PNTG, and MDXG Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q4 2024	BSEM BioStem Technologies	$1.25	$0.17	-$1.08	$0.17	$101.20 million	$72.53 million
5/8/2025	Q1 2025	COLL Collegium Pharmaceutical	$1.50	$1.49	-$0.01	$0.07	$174.96 million	$177.76 million
4/30/2025	Q1 2025	MDXG MiMedx Group	$0.06	$0.06	N/A	$0.05	$86.32 million	$88.21 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BSEM BioStem Technologies	N/A	N/A	N/A	N/A	N/A
COLL Collegium Pharmaceutical	N/A	N/A	N/A	N/A	N/A
MDXG MiMedx Group	N/A	N/A	N/A	N/A	N/A
PNTG The Pennant Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BSEM BioStem Technologies	N/A	N/A	N/A
COLL Collegium Pharmaceutical	3.30	1.08	1.01
MDXG MiMedx Group	0.09	4.70	4.13
PNTG The Pennant Group	0.81	1.41	1.41

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BSEM BioStem Technologies	N/A
COLL Collegium Pharmaceutical	N/A
MDXG MiMedx Group	79.15%
PNTG The Pennant Group	85.88%

Insider Ownership

Company	Insider Ownership
BSEM BioStem Technologies	N/A
COLL Collegium Pharmaceutical	2.51%
MDXG MiMedx Group	1.70%
PNTG The Pennant Group	5.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BSEM BioStem Technologies	N/A	16.70 million	N/A	N/A
COLL Collegium Pharmaceutical	210	32.13 million	31.33 million	Optionable
MDXG MiMedx Group	870	147.70 million	145.19 million	Optionable
PNTG The Pennant Group	7,000	34.47 million	32.61 million	Optionable

BSEM, COLL, PNTG, and MDXG Headlines

Recent News About These Companies

The Pennant Group (NASDAQ:PNTG) Earns Overweight Rating from Stephens

June 12, 2025 | americanbankingnews.com

Stephens Reaffirms "Overweight" Rating for The Pennant Group (NASDAQ:PNTG)

June 10, 2025 | marketbeat.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Buys 14,020 Shares of The Pennant Group, Inc. (NASDAQ:PNTG)

June 8, 2025 | marketbeat.com

Squarepoint Ops LLC Takes Position in The Pennant Group, Inc. (NASDAQ:PNTG)

June 6, 2025 | marketbeat.com

Mackenzie Financial Corp Invests $475,000 in The Pennant Group, Inc. (NASDAQ:PNTG)

June 4, 2025 | marketbeat.com

Wells Fargo & Company Issues Positive Forecast for The Pennant Group (NASDAQ:PNTG) Stock Price

June 3, 2025 | marketbeat.com

ProShare Advisors LLC Buys New Shares in The Pennant Group, Inc. (NASDAQ:PNTG)

June 1, 2025 | marketbeat.com

The Pennant Group, Inc. (NASDAQ:PNTG) Shares Purchased by Bank of America Corp DE

June 1, 2025 | marketbeat.com

Is There Now An Opportunity In The Pennant Group, Inc. (NASDAQ:PNTG)?

May 30, 2025 | finance.yahoo.com

Voloridge Investment Management LLC Makes New Investment in The Pennant Group, Inc. (NASDAQ:PNTG)

May 30, 2025 | marketbeat.com

Two Sigma Investments LP Has $4.11 Million Holdings in The Pennant Group, Inc. (NASDAQ:PNTG)

May 30, 2025 | marketbeat.com

Millennium Management LLC Boosts Stock Position in The Pennant Group, Inc. (NASDAQ:PNTG)

May 30, 2025 | marketbeat.com

Two Sigma Advisers LP Acquires 77,900 Shares of The Pennant Group, Inc. (NASDAQ:PNTG)

May 28, 2025 | marketbeat.com

Nuveen Asset Management LLC Increases Holdings in The Pennant Group, Inc. (NASDAQ:PNTG)

May 28, 2025 | marketbeat.com

Joanne Stringfield Sells 5,000 Shares of The Pennant Group, Inc. (NASDAQ:PNTG) Stock

May 24, 2025 | insidertrades.com

PharVision Advisers LLC Invests $304,000 in The Pennant Group, Inc. (NASDAQ:PNTG)

May 24, 2025 | marketbeat.com

Zimmer Partners LP Invests $3.98 Million in The Pennant Group, Inc. (NASDAQ:PNTG)

May 23, 2025 | marketbeat.com

Deutsche Bank AG Has $3.08 Million Holdings in The Pennant Group, Inc. (NASDAQ:PNTG)

May 23, 2025 | marketbeat.com

Pennant Group holds annual meeting, elects directors

May 21, 2025 | investing.com

PNTG Q1 Earnings Call: Acquisition Momentum and Organic Growth Drive Outperformance

May 20, 2025 | finance.yahoo.com

BNP Paribas Financial Markets Makes New $2.02 Million Investment in The Pennant Group, Inc. (NASDAQ:PNTG)

May 20, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Defense Stocks That Will Profit From a Golden Dome
By Chris Markoch | May 30, 2025
View 3 Defense Stocks That Will Profit From a Golden Dome
Analysts Think These Stocks Could More Than Double in Value
By Nathan Reiff | May 23, 2025
View Analysts Think These Stocks Could More Than Double in Value
Intel’s Turnaround May Be the Best Bet No One’s Watching
By Jeffrey Neal Johnson | May 30, 2025
View Intel’s Turnaround May Be the Best Bet No One’s Watching
Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
By Thomas Hughes | May 27, 2025
View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
Tesla Bulls and Bears Collide: What Investors Should Know
By Sam Quirke | June 18, 2025
View Tesla Bulls and Bears Collide: What Investors Should Know

BSEM, COLL, PNTG, and MDXG Company Descriptions

BioStem Technologies OTCMKTS:BSEM

$13.11 -1.04 (-7.35%)

As of 06/18/2025 03:57 PM Eastern

BioStem Technologies, Inc., a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases. The company is also engages in the repackaging and distribution of active pharmaceutical ingredients and other pharmaceutical compounding supplies; and develops and markets nutraceutical products under the Dr. Dave's Best and Nesvik Organics brands, as well as other non-proprietary products in the United States and internationally. The company sells products through e-commerce platforms. BioStem Technologies, Inc. was incorporated in 2006 and is based in Pompano Beach, Florida.

Collegium Pharmaceutical NASDAQ:COLL

$29.60 +0.16 (+0.54%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$29.60 0.00 (0.00%)

As of 06/18/2025 04:04 PM Eastern

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

MiMedx Group NASDAQ:MDXG

$5.90 +0.05 (+0.85%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$6.00 +0.09 (+1.61%)

As of 06/18/2025 05:29 PM Eastern

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; and EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications. The company's products have applications in the areas of wound care, burn, surgical sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia.

The Pennant Group NASDAQ:PNTG

$28.06 +0.19 (+0.68%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$28.09 +0.03 (+0.11%)

As of 06/18/2025 04:40 PM Eastern

The Pennant Group, Inc. provides healthcare services in the United States. It operates in two segments, Home Health and Hospice Services, and Senior Living Services. The company offers home health services, including clinical services, such as nursing, speech, occupational and physical therapy, medical social work, and home health aide services; and hospice services comprising clinical care, education, and counseling services for the physical, spiritual, and psychosocial needs of terminally ill patients and their families. It also provides senior living services, such as residential accommodations, activities, meals, housekeeping, and assistance in the activities of daily living to seniors who are independent or who require some support. The company operates home health, hospice, and home care agencies, as well as senior living communities throughout Arizona, California, Colorado, Idaho, Montana, Nevada, Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin, and Wyoming. The Pennant Group, Inc. was incorporated in 2019 and is headquartered in Eagle, Idaho.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time